EXHIBIT 99.1

         ARIAD To Host Analyst Conference Call June 15, 2004;
            Audio May Be Accessed By Webcast Or Telephone

    CAMBRIDGE, Mass.--(BUSINESS WIRE)--June 9, 2004--ARIAD
Pharmaceuticals, Inc. (Nasdaq: ARIA) today announced that it will host
a conference call for biotechnology investment analysts on Tuesday,
June 15, 2004, at 11 a.m. (ET). The Company's senior management will
discuss the clinical results of its lead oncology product candidate,
AP23573, which were summarized in a press release issued June 7, and
its plans for advancing the clinical development of this product
candidate, which will be released before the market opens on June 15.
    Biotechnology industry analysts associated with investment banks
and institutional funds are invited to call ARIAD's investor relations
office at 610-407-9260 to obtain information that will enable them to
participate in the Q&A of the conference call.
    A direct link to a live audio webcast of the conference call can
be accessed at ARIAD's website (http://www.ariad.com/investor) by
clicking on this link. An archived audio webcast also will be
available beginning approximately two hours after completion of the
conference call until 5:00 p.m. (ET) on Tuesday, June 22, 2004. To
ensure a timely connection to the live webcast, it is recommended that
participants register at least fifteen minutes prior to the scheduled
webcast.
    Alternatively, the conference call can be heard by calling
888-842-0024 (U.S.) or 617-801-9702 (international) and providing the
pass code number 52889596. Telephone replay will be available
beginning approximately two hours after completion of the conference
call until 5:00 p.m. (ET) on Tuesday, June 22, 2004. To access the
replay, please call 888-286-8010 (U.S.) or 617-801-6888
(international) and provide the pass code number 89039170
    ARIAD is engaged in the discovery and development of breakthrough
medicines to treat cancer by regulating cell signaling with small
molecules. The Company is developing a comprehensive approach to
patients with cancer that addresses the greatest medical need -
aggressive and advanced-stage cancers for which current treatments are
inadequate. ARIAD also has an exclusive license to pioneering
technology and patents related to certain NF-(kappa)B treatment
methods, and the discovery and development of drugs to regulate
NF-(kappa)B cell-signaling activity.

    Additional information about ARIAD can be found on the web at
http://www.ariad.com.

    Some of the matters discussed herein are "forward-looking
statements" within the meaning of the Private Securities Litigation
Reform Act of 1995. Such statements are identified by the use of words
such as "anticipate," "estimate," "expect," "project," "intend,"
"plan," "believe," and other words and terms of similar meaning in
connection with any discussion of future operating or financial
performance. Such statements are based on management's current
expectations and are subject to certain factors, risks and
uncertainties that may cause actual results, outcome of events, timing
and performance to differ materially from those expressed or implied
by such forward-looking statements. These risks include, but are not
limited to, risks and uncertainties regarding the Company's ability to
conduct preclinical and clinical studies of its product candidates,
risks and uncertainties that clinical trial results at any phase of
development may be adverse or may not be predictive of future results
or lead to regulatory approval of any of the Company's product
candidates, and risks and uncertainties relating to regulatory
oversight, intellectual property claims, the timing, scope, cost and
outcome of legal proceedings, future capital needs, key employees,
dependence on the Company's collaborators and manufacturers, markets,
economic conditions, products, services, prices, reimbursement rates,
competition and other risks detailed in the Company's public filings
with the Securities and Exchange Commission, including ARIAD's Annual
Report on Form 10-K for the fiscal year ended December 31, 2003. The
information contained in this document is believed to be current as of
the date of original issue. The Company does not intend to update any
of the forward-looking statements after the date of this document to
conform these statements to actual results or to changes in the
Company's expectations, except as required by law.

    CONTACT: ARIAD Pharmaceuticals, Inc.
             Tom Pearson, 610-407-9260
             or
             Kathy Lawton, 617-621-2345